Delray Beach, FL, Aug. 22, 2025 (GLOBE NEWSWIRE) -- The global liquid biopsy market, valued at US$3.65 billion in 2024, stood at US$4.03 billion in 2025 and is projected to advance at a resilient CAGR of 11.8% from 2025 to 2030, culminating in a forecasted valuation of US$7.05 billion by the end of the period. Driven by rising cancer incidence, accelerating adoption of precision medicine, and significant technological advancements, liquid biopsy is emerging as a cornerstone in early disease detection, oncology care, and personalized medicine.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350
Transforming Cancer Detection and Treatment
What is driving this surge? The growing global cancer burden is the primary catalyst. Liquid biopsy offers a minimally invasive, repeatable alternative to tissue biopsies—enabling clinicians to detect circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers through a simple blood test. This provides oncologists with real-time insights into tumor dynamics, helping guide timely and accurate treatment decisions.
Why does it matter now? With cancer cases climbing worldwide, healthcare systems are under pressure to adopt faster, safer, and more cost-effective diagnostics. Liquid biopsy not only supports early detection but also allows physicians to track therapeutic resistance and adjust treatment strategies accordingly—improving outcomes and reducing overall costs.
Expanding Clinical Applications Beyond Oncology
Where is liquid biopsy making new inroads? Beyond cancer care, its applications are rapidly expanding into non-invasive prenatal testing and organ transplantation monitoring. In both fields, liquid biopsy provides actionable insights without the risks associated with invasive procedures.
How is technology reshaping the market? Innovations such as next-generation sequencing (NGS), digital PCR, and enhanced biomarker detection methods are improving the sensitivity, reliability, and clinical utility of liquid biopsy assays. These breakthroughs are making liquid biopsy an indispensable tool across a wider spectrum of healthcare settings.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350
Market Dynamics: Opportunities and Challenges
- Driver: Rising incidence of cancer worldwide.
- Opportunity: Growing significance of companion diagnostics—enabling precise patient-therapy matching and fueling collaborations between pharma and diagnostics companies.
- Restraint: Limited sensitivity and specificity in some procedures, leading to false negatives.
- Challenge: Unfavorable reimbursement scenarios remain a barrier, with complex, inconsistent coverage policies limiting access and affordability.
Market Ecosystem and Regional Outlook
Who are the key stakeholders? End users include reference laboratories, hospitals, physician labs, and academic research centers. Among biomarkers, ctDNA is expected to witness the fastest growth, driven by its ability to provide actionable tumor insights for precision oncology. By sample type, blood remains the dominant medium due to its convenience, safety, and extensive clinical validation.
Where is growth strongest? North America currently leads the global market, supported by advanced healthcare infrastructure and strong R&D investments. However, the Asia Pacific region is forecasted to record the highest growth rate, fueled by increasing cancer prevalence, government support, and rising healthcare expenditures.
Competitive Landscape and Recent Developments
The market is shaped by leading players including Natera, Guardant Health, Myriad Genetics, Illumina, F. Hoffmann-La Roche, QIAGEN, Thermo Fisher Scientific, Bio-Rad Laboratories, Exact Sciences, and Sysmex Corporation, among others.
Recent strategic moves highlight an innovation-driven race:
- April 2025: Natera launched its ultra-sensitive Signatera Genome-MRD test in the US.
- February 2025: Myriad Genetics partnered with Gabbi, a telehealth breast cancer care provider, integrating risk assessment with hereditary cancer testing.
- June 2025: Guardant Health’s Shield multi-cancer detection test received FDA Breakthrough Device designation.
- Earlier expansions: Illumina’s launch of the TruSight Oncology 500 ctDNA v2 and Natera’s acquisition of Invitae’s non-invasive prenatal screening assets strengthened portfolios.
Strategic Implications for Decision-Makers
For C-suite executives, the implications are clear: liquid biopsy is no longer a niche diagnostic innovation but a strategic enabler for precision medicine, risk reduction, and healthcare cost containment. Its integration into oncology, reproductive health, and transplantation care underscores its role in shaping the future of global healthcare delivery.
For more information, Inquire Now!
Discover Connected Healthcare Market Opportunities:
Wound Care Market
Biotechnology Contract Manufacturing Market
Artificial Intelligence (AI) in Healthcare Market
Refurbished Medical Equipment Market
Home Healthcare Market
Get access to the latest updates on Top Companies in Liquid Biopsy and Liquid Biopsy Market Size
